469 related articles for article (PubMed ID: 30740244)
1. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
RMD Open; 2019; 5(1):e000836. PubMed ID: 30740244
[TBL] [Abstract][Full Text] [Related]
2. Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice.
Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
RMD Open; 2019; 5(2):e001050. PubMed ID: 31908842
[TBL] [Abstract][Full Text] [Related]
3. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
4. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.
Olsen IC; Lie E; Vasilescu R; Wallenstein G; Strengholt S; Kvien TK
Rheumatology (Oxford); 2019 Mar; 58(3):481-491. PubMed ID: 30508189
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
[TBL] [Abstract][Full Text] [Related]
6. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.
Bergstra SA; Allaart CF; Stijnen T; Landewé RBM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1473-1483. PubMed ID: 27992656
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S
J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
[TBL] [Abstract][Full Text] [Related]
8. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
[TBL] [Abstract][Full Text] [Related]
9. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
[TBL] [Abstract][Full Text] [Related]
10. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
[TBL] [Abstract][Full Text] [Related]
11. Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study.
Gaubitz M; Göttl KH; Behmer O; Lippe R; Meng T; Löschmann PA
Clin Rheumatol; 2017 Sep; 36(9):1989-1996. PubMed ID: 28756532
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
[TBL] [Abstract][Full Text] [Related]
13. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories.
Pincus T; Swearingen CJ; Bergman M; Yazici Y
J Rheumatol; 2008 Nov; 35(11):2136-47. PubMed ID: 18793006
[TBL] [Abstract][Full Text] [Related]
14. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients.
Shi ZC; Fei HP; Wang ZL
Medicine (Baltimore); 2020 Jan; 99(3):e16635. PubMed ID: 32011430
[TBL] [Abstract][Full Text] [Related]
16. Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
Bergstra SA; Allaart CF; van den Berg R; Chopra A; Govind N; Huizinga TWJ; Landewe RBM
Arthritis Res Ther; 2017 Nov; 19(1):258. PubMed ID: 29166919
[TBL] [Abstract][Full Text] [Related]
17. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
Dale J; Stirling A; Zhang R; Purves D; Foley J; Sambrook M; Conaghan PG; van der Heijde D; McConnachie A; McInnes IB; Porter D
Ann Rheum Dis; 2016 Jun; 75(6):1043-50. PubMed ID: 27026689
[TBL] [Abstract][Full Text] [Related]
18. Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results.
Lau AN; Thorne JC; Movahedi M; Rampakakis E; Cesta A; Li X; Couto S; Sampalis J; Bombardier C;
J Rheumatol; 2019 Aug; 46(8):874-886. PubMed ID: 30988121
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
20. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
Keystone EC; Ahmad HA; Yazici Y; Bergman MJ
Rheumatology (Oxford); 2020 Aug; 59(8):2090-2098. PubMed ID: 31819995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]